Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synta encouraged by phase II Crohn’s disease data
STA-5326 is the first oral, small-molecule, and highly selective inhibitor of the IL-12 cytokine family, including IL-12 and IL-23, cytokines that play a central role in Crohn’s disease
STA-5326 is the first oral, small-molecule, and highly selective inhibitor of the IL-12 cytokine family, including IL-12 and IL-23, cytokines that play a central role in Crohn’s disease
Teva’s Clarithromycin extended release tablets are the AB-rated generic equivalent of Abbott’s macrolide antibiotic Biaxin XL Filmtabs. The Abbott branded product has annual sales of approximately $284 million,
Invirase (saquinavir mesylate) will remain on the market in both 500mg tablets and 200mg capsules, while Fortovase (saquinavir) will be discontinued during the first quarter of 2006. According
Under the agreement, Morphotek’s proprietary Morphodoma technology will be applied to GSK’s antibody producer lines to generate the cell lines. Morphotek will receive funding to support R&D efforts
Genmab purchased all of Europroteome’s rights, including patent applications and know-how from the company’s insolvency administrator, and does not owe anything further to the insolvency estate. The Danish
Sinovac and LG began meeting in March 2005 to discuss and establish their mutual interests in the commercial vaccine industry. As a result of subsequent meetings and discussions,
NGX-4010 is NeurogesX’s novel high-concentration trans-capsaicin dermal patch. In the trial, patients reported statistically significant pain reduction over a 12-week period following a single application of NGX-4010, the
The license agreement provides Neurologix with exclusive worldwide rights (excluding Japan) to develop and commercialize therapeutics to treat brain and other CNS disorders (excluding amyotrophic lateral sclerosis) using
In new results from a trial that pitted Diovan (valsartan) against another blood pressure drug, amlodipine (marketed as Norvasc by Pfizer), patients taking valsartan were found to have
Data from a trial named IMPACT 2 served as the primary basis for the approval. In the trial, significant improvements in both American College of Rheumatology and psoriasis